SEC filing re PFIZER, revenue and Alandail summary from RB #13851
From the 10-K
On November 1, 2001, MultiCell entered into a collaborative research agreement with Pfizer, Inc. pursuant to which Pfizer paid $724,500 to validate the efficacy of MultiCell's immortalized hepatic cells in four different experimental models. These cells, if effective, could replace the current hepatocytes used by Pfizer as well as other pharmaceutical companies. The efficacy of these cell lines was demonstrated and presented by Pfizer at the International Society for the Study of Xenobiotics ("ISSX") in October 2002.
This led to the validation they needed that first led to this being in the May 31 Q
The Company has had discussions with more than a dozen companies interested in acquiring our engineered cells for research. We have received orders from three major pharmaceutical companies where efficacy evaluation is currently taking place. We believe that some of these discussions and evaluations can be brought to a conclusion in the near future. The agreements may produce cash to use for operations and research.
And also led to the deal with XenoTech - XenoTech saw Pfizer's presentation and first did their own validation and then went after EXTI to make that $18 million guaranteed minimum deal. We also know Roche has now validated and extended Pfizers results.
Sure, there is a process involved in getting companies to switch over to EXTI's cell lines. But don't think that process just started a few weeks ago - the process has been going on for at least 6 months now. Roche did this research and concluded in their presentation:
In summary, Fa2N-4 cells are a convenient and viable alternative to primary human hepatocytes for evaluating the potential of investigational compounds to induce Drug Metabolizing Enzymes and Drug Transporters.
Wouldn't it be a fair conclusion that anyone who did this research and reached these conclusions would already be a customer for XenoTech?
- - - - -
News 
Market Data 
Discover 
AI
